Wilmington Savings Fund Society FSB Sells 5,627 Shares of Amgen Inc. $AMGN

Wilmington Savings Fund Society FSB decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 9.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 51,576 shares of the medical research company’s stock after selling 5,627 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Amgen were worth $14,555,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in AMGN. Brighton Jones LLC lifted its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC increased its position in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. increased its position in shares of Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares during the last quarter. Alberta Investment Management Corp purchased a new position in shares of Amgen during the 2nd quarter valued at about $474,000. Finally, LSV Asset Management lifted its position in Amgen by 176.7% in the 2nd quarter. LSV Asset Management now owns 301,100 shares of the medical research company’s stock worth $84,070,000 after buying an additional 192,300 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HSBC reaffirmed a “buy” rating and issued a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. Argus boosted their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Citigroup increased their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Finally, Piper Sandler boosted their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $354.00.

Amgen Trading Down 1.4%

Shares of AMGN opened at $361.13 on Wednesday. The stock has a market capitalization of $194.67 billion, a P/E ratio of 25.38, a PEG ratio of 3.63 and a beta of 0.45. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a fifty day simple moving average of $359.26 and a two-hundred day simple moving average of $326.77.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.8%. Amgen’s dividend payout ratio (DPR) is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.